Abrysvo Real-World Evidence 2026: Maternal RSV Vaccination Cuts Infant Hospital Admissions by 82% | iMedic

Why Does Real-World Evidence for Abrysvo Matter More Than Clinical Trial Data Alone?

Randomized controlled trials like MATISSE remain the gold standard for establishing vaccine efficacy, but they inherently operate under ideal conditions. The MATISSE trial enrolled approximately 7,400 pregnant individuals across 18 countries, yet participants were screened for eligibility and closely monitored in ways that do not reflect routine clinical practice. Real-world effectiveness studies address this gap by evaluating outcomes among the general population, including individuals with comorbidities, varying socioeconomic backgrounds, and inconsistent access to prenatal care.

During the 2025-2026 RSV season, pediatric surveillance networks tracked hospitalization rates among infants whose mothers received Abrysvo during routine prenatal visits compared with infants of unvaccinated mothers. The consistency between trial efficacy (81.8% against severe disease within 90 days) and observed real-world effectiveness is particularly reassuring because it suggests the vaccine performs reliably outside of controlled research environments. This finding also addresses a concern raised by some clinicians who questioned whether the relatively wide confidence interval in the MATISSE trial (40.6–96.3%) might indicate variable real-world performance. The emerging observational data suggest that the point estimate of approximately 82% is robust and reproducible.

How Does the Timing of Abrysvo Administration Affect Neonatal Protection?

Transplacental antibody transfer is an active immunological process that requires adequate time between maternal immunization and delivery for antibody levels to peak and cross the placenta efficiently. Data from both the MATISSE trial and subsequent pharmacokinetic analyses indicate that maternal anti-RSV prefusion F protein antibodies reach maximum serum concentrations roughly two weeks after vaccination. The FDA-approved administration window of 32 to 36 weeks of gestation was selected to balance maximizing antibody transfer with minimizing theoretical preterm birth risk.

Real-world surveillance has provided additional granularity on this timing relationship. Infants born fewer than 14 days after maternal vaccination appear to have lower cord blood antibody levels, correlating with modestly reduced protection during the first weeks of life. Conversely, infants born more than 60 days post-vaccination show adequate initial antibody levels but may experience earlier waning of protection, potentially leaving them vulnerable during the latter portion of the RSV season. These observations have practical implications for obstetric counseling: clinicians are encouraged to administer Abrysvo early in the recommended gestational window when RSV season onset is imminent, ensuring that the infant is born within the optimal antibody transfer period.

What Are the Major Barriers to Achieving Broader Maternal RSV Vaccine Coverage?

Achieving high vaccination coverage among pregnant individuals has historically been challenging even for well-established vaccines such as influenza and Tdap. Abrysvo faces additional hurdles as a relatively new product with a complex public narrative. The initial FDA advisory committee discussion in 2023 included extensive debate about a potential preterm birth signal, which — although the subsequent restricted gestational window and post-marketing data have been reassuring — left a lasting impression on both clinicians and patients. Surveys of obstetricians conducted during the 2025-2026 season suggest that while a majority support the vaccine in principle, many report uncertainty about how to counsel patients regarding the preterm birth question.

Insurance and logistical barriers compound the problem. Some commercial insurers have been slow to cover Abrysvo without cost-sharing, and Vaccines for Children program coverage does not directly apply to adult prenatal vaccines. Additionally, the seasonal recommendation window creates a narrow period during which eligible patients must be identified, counseled, and vaccinated — a workflow challenge for busy obstetric practices. Public health experts have advocated for integrating RSV vaccination counseling into routine prenatal care protocols alongside Tdap and influenza vaccination, noting that bundled recommendations from trusted providers remain the strongest predictor of vaccine acceptance during pregnancy.